Axillary sentinel lymph node identification using superparamagnetic iron oxide versus radioisotope in early stage breast cancer: The UK SentiMag trial (SMART study)

被引:4
|
作者
Vidya, Raghavan [1 ]
Khosla, Muskaan [1 ,6 ]
Laws, Siobhan [2 ]
Harvey, James [3 ]
Kaushik, Monika [4 ]
Mullapudi, Naga A. [1 ]
Macmillan, Douglas [5 ]
机构
[1] Royal Wolverhampton NHS Trust, Breast Surg, Wolverhampton, England
[2] Royal Hampshire Cty Hosp, Breast Surg, Winchester, Hants, England
[3] Manchester Univ NHS Fdn Trust, Wythenshawe Hosp, Nightingale Breast Canc Ctr, Manchester, England
[4] Glenfield Hosp, Breast Surg, Groby Rd, Leicester, England
[5] Nottingham Univ Hosp NHS Trust, Nottingham, England
[6] Royal Wolverhampton NHS Trust, Wolverhampton, England
关键词
Breast cancer; Sentinel node biopsy; Techniques; BIOPSY; METAANALYSIS; DISSECTION; TC-99;
D O I
10.1016/j.surge.2022.04.006
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background & Objectives: Sentinel lymph node biopsy (SLNB) is an accurate and reliable method for staging the axilla in early breast cancer. The gold standard technique for localizing the sentinel lymph node (SLN) is the use of radioisotope with or without blue dye. However, this technique has its limitations. Various alternatives have been explored to overcome the disadvantages of the standard SLNB technique and superparamagnetic iron oxide mapping agents have garnered significant attention. The SMART study aims to compare the magnetic technique using the superparamagnetic iron oxide particles (SPIO, Sienna+(R)) to the radioisotope technique (Tc99) +/- blue dye, for SLN identification in patients with early breast cancer.Methods: A prospective, multicenter study was done that recruited 109 clinically nodenegative early-stage breast cancer patients from five centres in the United Kingdom (UK). The patients received radioisotope +/- blue dye injections, followed by intraoperative injection of magnetic tracer prior to SLNB. The sentinel node identification rate was compared between the magnetic and standard techniques to evaluate detection rate (per patient and per node), non-inferiority and concordance.Results: Data was analysed for 107 patients. The per patient detection rate was 98.13% (105/ 107) when using the magnetic tracer and 92.26% (103/107) when using the standard technique. The nodal detection rate was 93.07% (188/202 nodes) when using the magnetic tracer and 96.53% (195/202) when using the standard technique. Of the 31 patients with positive sentinel lymph nodes (SLNs), all 31 (100%) were detected by both techniques.Conclusion: Our study demonstrates that the magnetic technique is a feasible method for SLNB, with an identification rate that is not inferior to the standard technique. The magnetic technique offers a suitable alternative to the standard technique thereby avoiding the need for the complexities of nuclear medicine, the hazards of radiation and the anaphylaxis risk of blue dye.(c) 2022 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:128 / 134
页数:7
相关论文
共 50 条
  • [1] Sentinel Lymph Node Identification Using Super Paramagnetic Iron Oxide versus Radioisotope: the UK SentiMag Trial (SMART Study)
    Sukumar, A.
    AmulyaMullapadi, N.
    Salem, F.
    Ahmed, S.
    Vidya, R.
    BRITISH JOURNAL OF SURGERY, 2020, 107 : 16 - 16
  • [2] Sentinel Lymph Node Identification Using Superparamagnetic Iron Oxide Particles Versus Radioisotope: The French Sentimag Feasibility Trial
    Houpeau, Jean-Louis
    Chauvet, Marie-Pierre
    Guillemin, Francois
    Bendavid-Athias, Cecile
    Charitansky, Helene
    Kramar, Andrew
    Giard, Sylvia
    JOURNAL OF SURGICAL ONCOLOGY, 2016, 113 (05) : 501 - 507
  • [3] The SentiMag study: Sentinel node biopsy with superparamagnetic iron oxide vs. radioisotope
    Thill, M.
    Kurylcio, A.
    Blechmann, R.
    van Haasteren, V.
    Grosse, B.
    Berclaz, G.
    Polkowski, W.
    Hauser, N.
    CANCER RESEARCH, 2013, 73
  • [4] The Central European SentiMag® Studies; Sentinel node biopsy with superparamagnetic iron oxide (SPIO) versus radioisotope
    Thill, M.
    Kurylcio, A.
    Welter, R.
    Baumann, K.
    van Haasteren, V.
    Grosse, B.
    Berclaz, G.
    Polkowski, W.
    Hauser, N.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S149 - S149
  • [5] The SentiMag Study: Sentinel node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope
    Thill, M.
    Kurylcio, A.
    Blechmann, R.
    Van Haasteren, V.
    Grosse, B.
    Berclaz, G.
    Polkowski, W.
    Hauser, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S260 - S261
  • [6] The Central-European SentiMag study: Sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope
    Thill, Marc
    Kurylcio, Andrzej
    Welter, Rebekka
    van Haasteren, Viviana
    Grosse, Britta
    Berclaz, Gilles
    Polkowski, Wojciech
    Hauser, Nik
    BREAST, 2014, 23 (02): : 175 - 179
  • [7] Pre-operative sentinel lymph node localization in breast cancer with superparamagnetic iron oxide MRI: the SentiMAG Multicentre Trial imaging subprotocol
    Pouw, Joost J.
    Grootendorst, Maarten R.
    Bezooijen, Roland
    Klazen, Caroline A. H.
    De Bruin, Wieger I.
    Klaase, Joost M.
    Hall-Craggs, Margaret A.
    Douek, Michael
    ten Haken, Bennie
    BRITISH JOURNAL OF RADIOLOGY, 2015, 88 (1056):
  • [8] Sentinel Lymph Node Biopsy in Patients with Breast Cancer Using Superparamagnetic Iron Oxide and a Magnetometer
    Shiozawa, M.
    Lefor, A.
    Hozumi, Y.
    Kurihara, K.
    Sata, N.
    Yasuda, Y.
    Kusakabe, M.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S59 - S59
  • [9] Sentinel lymph node biopsy in patients with breast cancer using superparamagnetic iron oxide and a magnetometer
    Shiozawa, Mikio
    Lefor, Alan T.
    Hozumi, Yasuo
    Kurihara, Katsumi
    Sata, Naohiro
    Yasuda, Yoshikazu
    Kusakabe, Moriaki
    BREAST CANCER, 2013, 20 (03) : 223 - 229
  • [10] Sentinel lymph node biopsy in patients with breast cancer using superparamagnetic iron oxide and a magnetometer
    Mikio Shiozawa
    Alan T. Lefor
    Yasuo Hozumi
    Katsumi Kurihara
    Naohiro Sata
    Yoshikazu Yasuda
    Moriaki Kusakabe
    Breast Cancer, 2013, 20 : 223 - 229